Compare · LNTH vs OCX
LNTH vs OCX
Side-by-side comparison of Lantheus Holdings Inc. (LNTH) and Oncocyte Corporation (OCX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LNTH and OCX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- LNTH is the larger of the two at $6.57B, about 44.0x OCX ($149.4M).
- LNTH has been more active in the news (17 items in the past 4 weeks vs 1 for OCX).
- LNTH has more recent analyst coverage (17 ratings vs 9 for OCX).
- Company
- Lantheus Holdings Inc.
- Oncocyte Corporation
- Price
- -
- -
- Market cap
- $6.57B
- $149.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- AMEX
- IPO
- 2015
- News (4w)
- 17
- 1
- Recent ratings
- 17
- 9
Lantheus Holdings Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM Toyama Chemical Co. Ltd.; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Oncocyte Corporation
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation has a strategic collaboration with Gruppo Oncologico del Nord-Ovest of Pisa to evaluate DetermaIO as a biomarker for immunotherapy response in metastatic colorectal cancer; and Echelon Diagnostics, Inc. The company was founded in 2009 and is headquartered in Irvine, California.
Latest LNTH
- Director Ber Gerard covered exercise/tax liability with 381 shares, decreasing direct ownership by 1% to 27,118 units (SEC Form 4)
- Executive Chair and CEO Heino Mary Anne covered exercise/tax liability with 1,227 shares, decreasing direct ownership by 0.38% to 321,897 units (SEC Form 4)
- Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI's Image of the Year
- SEC Form SD filed by Lantheus Holdings Inc.
- Lantheus to Present at the William Blair 46th Annual Growth Stock Conference
- Lantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting
- Lantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
- Director Mchugh Julie was granted 4,137 shares, increasing direct ownership by 16% to 30,099 units (SEC Form 4)
- Director Morrow Phuong Khanh was granted 4,137 shares, increasing direct ownership by 133% to 7,237 units (SEC Form 4)
Latest OCX
- InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors
- Director Arno Andrew was granted 55,000 shares, increasing direct ownership by 67% to 136,554 units (SEC Form 4)
- Director Silverman Lou was granted 35,000 shares, increasing direct ownership by 2,238% to 36,564 units (SEC Form 4)
- Director Last Andrew J. was granted 35,000 shares, increasing direct ownership by 776% to 39,509 units (SEC Form 4)
- Oncocyte Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Oncocyte Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville
- Medicare Boosts Reimbursement for Oncocyte's Flagship Technology
- SEC Form DEFA14A filed by Oncocyte Corporation
- SEC Form DEF 14A filed by Oncocyte Corporation